China Biologic Products

Executive Summary

China Biologic Products is a leading plasma-based biopharmaceutical company in China, specializing in the development and manufacture of plasma derivatives such as albumin, immunoglobulins, and coagulation factors. With over 1,000 employees and a network of plasma collection stations across the country, the company benefits from China's growing demand for plasma therapies, driven by an aging population and expanding healthcare coverage. The company has demonstrated steady revenue growth and maintains a strong market position as one of the few large-scale players in China's plasma industry. However, it faces challenges from regulatory scrutiny, pricing pressures, and competition from international peers. Looking ahead, the company is expected to continue expanding its plasma collection capacity and advancing its product pipeline, with potential approvals for new variants of immunoglobulin therapies. The combination of a robust domestic market, limited competition due to high entry barriers, and a track record of consistent execution supports a positive long-term outlook, albeit with near-term risks related to regulatory changes and raw material shortages.

Upcoming Catalysts (preview)

• Q4 2026Approval of a new subcutaneous immunoglobulin product in China70% success
• TBDExpansion of plasma collection stations to over 50 facilities90% success
• Q3 2026Strategic partnership or licensing deal with a global biopharma for advanced coagulation factors40% success